FDF / DRUG PRODUCTS BIOLOGICS SERVICES OLIGONUCLEOTIDES in Europe
Development and manufacturing of oral solid dose (OSD), nasal, inhalation, and sterile dry powders and liquids drug products.
About the plant
Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.
Award-winning 60,000 sq.ft development and manufacturing facility in Nottingham, UK.
With over 25 years of experience, Upperton excels in rapid product introductions.
Our project delivery is unparalleled and designed specifically to align with the values and innovation of small to mid-sized pharma companies.
We are flexible and nimble, enabling rapid decision-making, problem-solving, collaboration, and product introduction within 4-6 weeks.
With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise covers all layers of our operations.
For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.
One site advantage
60,000 sq. ft development and manufacturing facility, Trent Gateway, in Nottingham, UK.
Development and manufacturing under one roof ensures your project moves smoothly from start to finish. With knowledge retained within the same team, handovers are minimised, communication stays clear, and risk is reduced at every stage. By combining development, scale-up, QC and manufacturing in one location, we provide a truly integrated, science-led approach that keeps your molecule on track and accelerates its path from pre-clinical studies to the clinic and market.
Our Manufacturing Capabilities at a Glance
- Up to 1,000,000 tableting capacity per day
- 500g – 205kg blending capacity
- Up to 2,000 blister packaging units per day
- Up to 50kg tablet coating per batch
- Up to 350,000 capsule filling (powder) capacity per day
- Up to 1000kg dry granulation capacity per day
- 0.5g – 10kg spray drying batch sizes (aqueous and solvent)
- 20 litres solution preparation vessels capacity with overhead mixing
- 10 state-of-the-art GMP manufacturing suites
Certifications
- MHRA (UK GMP)
Activity
- Abs (Antibodies), ADC & NDC (Antibody-drug), Peptide, protein, hormone & enzyme, Vaccines, Inhalation products, Oral liquids and semisolids, Oral solids / OSD, Sterile forms (ophtalmic, nasal, otic), Injectables, Powder, Nebulization, Bottles, Sprays, Oral solutions, Oral suspensions, Tablets, Hard capsules, Granules / Pellets, Powders, Terminal sterilization, Fill&Finish, Small volume vials, PFS (Prefilled Syringes), Cartridges, FDF / DRUG PRODUCTS, BIOLOGICS, SERVICES, OLIGONUCLEOTIDES manufacturing
Features
- Uses: Investigational, Commercial (Phase IV), Preclinical, Phase I, Phase II, Phase III, Human
- Toxicity (OEB classification): 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 5 / HPAPI (PDE < 10 µg/day)
- DEA: Schedule I (high potential for abuse / no medical use), Schedule II (high potential for abuse / medical use), Schedule III (lower potential for abuse), Schedule IV (low potential for abuse)
- BSL: 1
- Therapeutic areas: (C) Cardiovascular system, (N) Nervous system, (R) Respiratory system
- Markets: FDA (USA), EMA (EU), Health Canada (Canada), MHRA (UK), TGA (Australia)
Batch Size / Reactor
- Small, Medium
Services
- Regulatory services, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging, Preformulation studies, R&D, Formulation / Galenic design, QbD (Quality by Design), Process development, Process optimization, Process validation, Stability studies design, Stability studies execution, ICH Stability studies, Comparability studies, Downstream, Fill&Finish, Sterile product manufacturing, Non sterile product manufacturing, Tech transfer, Pilot plant, Formulation mixing, Research batches, Engineering batches, Scale-up, Pilot batches, Registration batches, Batch records, Analytical methods development, Analytical methods validation, Analytical methods transfer, QP in house, Batch certification / release, GMP documentation, Primary packaging, Secondary packaging, Labeling, CMC regulatory support, IND (Investigational New Drug aplication) filing support, IMPD (Investigational Medicinal Product Dossier) submission support
